These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 24663016

  • 1. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ, Barber KE, Ireland CE, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 4. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ.
    Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Steed ME, Werth BJ, Ireland CE, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167
    [Abstract] [Full Text] [Related]

  • 7. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [Abstract] [Full Text] [Related]

  • 8. Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation Ex Vivo Model.
    Kunz Coyne AJ, Stamper K, El Ghali A, Kebriaei R, Biswas B, Wilson M, Deschenes MV, Tran TT, Arias CA, Rybak MJ.
    Microbiol Spectr; 2023 Aug 17; 11(4):e0034023. PubMed ID: 37338375
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
    García P, Moscoso M, Fernández MC, Fuentes-Valverde V, Pérez A, Bou G.
    Int J Antimicrob Agents; 2023 Jul 17; 62(1):106836. PubMed ID: 37150362
    [Abstract] [Full Text] [Related]

  • 10. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2014 Jul 17; 58(2):672-7. PubMed ID: 24217694
    [Abstract] [Full Text] [Related]

  • 11. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model.
    Kunz Coyne AJ, Bleick C, Stamper K, Kebriaei R, Bayer AS, Lehman SM, Rybak MJ.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0138823. PubMed ID: 38376187
    [Abstract] [Full Text] [Related]

  • 12. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
    Kunz Coyne AJ, Stamper K, Bleick C, Kebriaei R, Lehman SM, Rybak MJ.
    Microbiol Spectr; 2024 Apr 02; 12(4):e0321223. PubMed ID: 38411110
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.
    Werth BJ, Shireman LM.
    Antimicrob Agents Chemother; 2017 Apr 02; 61(4):. PubMed ID: 28096164
    [Abstract] [Full Text] [Related]

  • 14. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.
    Kebriaei R, Rice SA, Stamper KC, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Apr 02; 63(4):. PubMed ID: 30670436
    [Abstract] [Full Text] [Related]

  • 15. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G.
    Antimicrob Agents Chemother; 2019 May 02; 63(5):. PubMed ID: 30858203
    [Abstract] [Full Text] [Related]

  • 16. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
    Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF.
    Antimicrob Agents Chemother; 2017 Mar 02; 61(3):. PubMed ID: 28232309
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
    MacVane SH, So W, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2014 Dec 02; 58(12):7520-6. PubMed ID: 25288076
    [Abstract] [Full Text] [Related]

  • 18. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F, de la Mària CG, Armero Y, Amat E, Soy D, Moreno A, del Río A, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM, Hospital Clinic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2008 Jul 02; 52(7):2538-43. PubMed ID: 18426900
    [Abstract] [Full Text] [Related]

  • 19. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
    Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK.
    Antimicrob Agents Chemother; 2012 Oct 02; 56(10):5296-302. PubMed ID: 22869564
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.
    Duss FR, Garcia de la Mària C, Croxatto A, Giulieri S, Lamoth F, Manuel O, Miró JM.
    J Antimicrob Chemother; 2019 Sep 01; 74(9):2626-2630. PubMed ID: 31298264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.